Pink Sheet is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Auxilium Widened Claims For Dupuytren's Contracture Drug Xiaflex, FDA Says

Executive Summary

Auxilium Pharmaceuticals' eagerness to draw attention to its new therapy for Dupuytren's disease, rather than any competitive pressure, has resulted in a speedy FDA "untitled" letter for a Xiaflex promotion
Advertisement

Related Content

Present Serious, Not Common, Risks First, FDA Tells Watson In Letter On Gelnique
Present Serious, Not Common, Risks First, FDA Tells Watson In Letter On Gelnique
Auxilium Sees Slow But Steady Progress With Xiaflex Launch
Auxilium Sees Slow But Steady Progress With Xiaflex Launch
Short Attention Span? Shire Cited Again For Out-Of-Bounds ADHD Promotion
Superiority Claims Based On Drug Delivery System Fail DDMAC Test
Auxilium's Xiaflex Clears FDA With REMS To Educate Doctors On Safe Injection Techniques
Auxilium's Xiaflex Clears FDA With REMS To Educate Doctors On Safe Injection Techniques
FDA Assesses Its Role In Limiting Physician Access To Auxilium's Xiaflex

Topics

Advertisement
UsernamePublicRestriction

Register

PS052407

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel